In a significant advancement for electrophysiology, Vancouver-based medical device innovator Kardium has received a Medical Device Licence from Health Canada for its flagship Globe Pulsed Field (PF) System. This regulatory milestone marks a homecoming for the technology, which was developed in Canada and has already begun to make waves in the United States following its FDA approval in 2025.
The Globe system represents a transformative approach to the treatment of atrial fibrillation (AF), a common cardiac rhythm disorder. By integrating high-density mapping and sophisticated ablation capabilities into a single, cohesive platform, Kardium is aiming to redefine the standard of care for cardiologists and their patients.
Main Facts: The Anatomy of the Globe System
The Globe Pulsed Field System is distinguished by its unique engineering, which addresses the dual clinical needs of cardiac mapping and tissue ablation. Unlike traditional systems that may require multiple catheters or separate devices, the Globe platform consolidates these tasks into a single, high-performance tool.
Integrated High-Density Mapping and Ablation
The core of the system is the Globe catheter, which features a spherical array of 122 individual electrodes. This high-density design allows for rapid, real-time mapping of the heart’s electrical activity. Once the target areas—typically the pulmonary veins—are identified, the same catheter can transition seamlessly to deliver pulsed field energy. This dual functionality enables physicians to perform single-shot pulmonary vein isolation (PVI) while also facilitating customizable, targeted ablation for more complex arrhythmia cases.
Precision Through Technology
A standout feature of the platform is its combination of real-time thermal contact sensing and advanced visualization tools. These features are critical for ensuring that ablation energy is delivered precisely to the intended tissue. By monitoring the quality of the contact between the catheter and the cardiac wall, the system provides physicians with the confidence to create durable lesions, thereby minimizing the risk of recurrence and improving long-term patient outcomes.
Chronology: A Trajectory of Innovation
The path to Health Canada approval is the culmination of years of rigorous research, clinical trials, and strategic regulatory navigation.
- Development Phase: Kardium, headquartered in Canada, focused its R&D efforts on creating a "one-stop" solution for electrophysiologists. The goal was to reduce procedural time and increase the efficacy of ablation therapies.
- The PULSAR Study: The clinical validation of the system was centered on the pivotal PULSAR study. The trial sought to prove that the Globe system was not only safe but also highly effective at maintaining sinus rhythm in patients with paroxysmal atrial fibrillation.
- 2025 FDA Approval: The company achieved a major international breakthrough when the US Food and Drug Administration (FDA) granted pre-market approval for the Globe system, alongside 510(k) clearance for the Globe introducer sheath and the proprietary mapping software.
- September 2025: Regulatory momentum continued as the FDA solidified the system’s status, setting the stage for commercial launch.
- October 2025: The first commercial procedures in the US were successfully completed, signaling the transition from clinical trial setting to real-world clinical practice.
- 2026 Health Canada Approval: With the receipt of its Canadian Medical Device Licence, Kardium has successfully brought its technology to its home market, ensuring that Canadian patients have access to the same state-of-the-art care as those in the US.
Supporting Data: Clinical Efficacy and Safety
The strength of the Globe system is anchored in the robust data produced during the PULSAR study. For medical professionals, the trial results serve as the primary evidence for the system’s clinical utility.
Key Outcomes of the PULSAR Study:
- Arrhythmia Freedom: One year post-procedure, 78% of patients with paroxysmal atrial fibrillation remained free from atrial arrhythmia, a testament to the durability of the lesions created by the system.
- Safety Profile: The study reported no device-related primary safety events, highlighting the controlled nature of the pulsed field energy delivery.
- Lesion Durability: A critical metric in cardiac ablation is the ability to create permanent, consistent lesions. The PULSAR study reported a 95% lesion durability rate, suggesting that the system significantly reduces the need for "touch-up" procedures.
These statistics are particularly compelling given the nature of pulsed field ablation, which is increasingly viewed as a more tissue-specific and safer alternative to traditional thermal (radiofrequency or cryo) ablation methods.
Official Responses: A Milestone for Canadian Biotech
The approval is a source of considerable pride for the Kardium team, reflecting both a commercial success and a validation of Canadian technological prowess.
Kardium CEO Kevin Chaplin expressed the significance of the event in a recent statement: "Health Canada approval represents another important milestone for Kardium and is especially meaningful as a Canada-based company. Following the successful introduction of the Globe system in the US, we are excited to bring this innovative technology to physicians and patients in Canada."
The sentiment underscores the company’s commitment to its roots. By securing approval at home, Kardium is not only expanding its market footprint but also fulfilling a mission to provide domestic patients with the most advanced cardiac care available globally.
Implications: The Future of Electrophysiology
The introduction of the Globe Pulsed Field System into the Canadian healthcare landscape has several profound implications for the medical community.
1. Streamlining Clinical Workflows
One of the most significant challenges in modern electrophysiology is the time spent in the lab. By allowing physicians to map and ablate with a single, versatile catheter, the Globe system can lead to shorter procedure times. This, in turn, can increase the number of patients treated per day, helping to reduce waitlists for cardiac care in provincial health systems.
2. Personalized Therapy
The flexibility of the Globe system is a departure from "one-size-fits-all" catheters. The ability to perform both single-shot isolation and highly targeted, customizable ablation means that physicians can tailor their strategy to the unique anatomy of each patient. This customization is particularly vital for patients whose AF is not isolated to the pulmonary veins but involves more complex electrical patterns in the left atrium.
3. Advancing Pulsed Field Ablation
Pulsed field ablation (PFA) is widely considered the next generation of energy delivery in cardiac medicine. Unlike radiofrequency ablation, which heats tissue, or cryoablation, which freezes it, PFA uses high-voltage, short-duration electrical pulses to create pores in the cell membranes of cardiac tissue—a process known as irreversible electroporation. This is highly selective for heart tissue, sparing surrounding structures like the esophagus and phrenic nerve. Kardium’s successful implementation of this technology places it at the forefront of this shift.
4. Economic and Healthcare Impact
With the aging population in Canada, the prevalence of atrial fibrillation is expected to rise. The burden on the healthcare system is substantial, ranging from hospitalizations for heart failure to the increased risk of stroke. By providing a system that improves long-term durability and reduces the likelihood of repeat procedures, Kardium is contributing to a more sustainable healthcare model.
Conclusion: A New Standard
The Globe Pulsed Field System is more than just a new tool in the electrophysiology lab; it is a manifestation of how high-density mapping and tissue-specific ablation can be synthesized for better patient care. As Kardium rolls out the system across Canada, the clinical community will be watching closely to see how the system’s real-world performance mirrors the impressive results of the PULSAR trial.
For now, the approval stands as a major achievement for Canadian innovation. It provides physicians with a powerful, flexible, and safe platform that addresses the core challenges of treating one of the world’s most common and complex cardiac conditions. As the company continues to expand its reach, the Globe system is well-positioned to become a cornerstone of cardiac rhythm management, offering renewed hope and improved quality of life for thousands of patients.
About the Author
